BioNTech (NASDAQ:BNTX) Stock: Insider Ugur Sahin Sells 34,000 Shares

BioNTech SE Sponsored ADR (NASDAQ:BNTX) CEO Ugur Sahin sold 34,000 shares of the business’s stock in a transaction that occurred on Monday, September 28th. The stock was sold at an average price of $98.47, for a total value of $3,347,980.00. Following the transaction, the chief executive officer owned 280,209 shares in the company, valued at approximately $27,592,180.23. This represents a 10.82% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Friday, September 25th, Ugur Sahin sold 27,000 shares of BioNTech stock. The shares were sold at an average price of $98.69, for a total value of $2,664,630.00.
• On Thursday, September 24th, Ugur Sahin sold 39,000 shares of BioNTech stock. The shares were sold at an average price of $98.99, for a total value of $3,860,610.00.
• On Wednesday, September 23rd, Ugur Sahin sold 30,000 shares of BioNTech stock. The stock was sold at an average price of $99.40, for a total value of $2,982,000.00.
• On Tuesday, September 22nd, Ugur Sahin sold 46,000 shares of BioNTech stock. The stock was sold at an average price of $100.72, for a total value of $4,633,120.00.
• On Monday, September 21st, Ugur Sahin sold 33,000 shares of BioNTech stock. The shares were sold at an average price of $97.81, for a total value of $3,227,730.00.
• On Friday, September 18th, Ugur Sahin sold 30,000 shares of BioNTech stock. The shares were sold at an average price of $96.22, for a total value of $2,886,600.00.
• On Thursday, September 17th, Ugur Sahin sold 34,000 shares of BioNTech stock. The stock was sold at an average price of $98.60, for a total value of $3,352,400.00.
• On Wednesday, September 16th, Ugur Sahin sold 15,000 shares of BioNTech stock. The stock was sold at an average price of $96.09, for a total value of $1,441,350.00.
• On Tuesday, September 15th, Ugur Sahin sold 34,000 shares of BioNTech stock. The stock was sold at an average price of $96.49, for a total value of $3,280,660.00.
• On Monday, September 14th, Ugur Sahin sold 41,000 shares of BioNTech stock. The shares were sold at an average price of $99.45, for a total transaction of $4,077,450.00.

BioNTech Trading Up 0.6%

Shares of BNTX traded up $0.56 during mid-day trading on Monday, reaching $99.08. The stock had a trading volume of 777,945 shares, compared to its average volume of 1,094,445. BioNTech SE Sponsored ADR has a 52-week low of $79.52 and a 52-week high of $124.00. The firm has a market cap of $25.06 billion, a price-to-earnings ratio of -12.65 and a beta of 1.29. The business’s fifty day moving average is $98.17 and its 200 day moving average is $94.74. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.85 and a quick ratio of 7.80.

BioNTech (NASDAQ:BNTX) last issued its earnings results on Tuesday, August 4th. The company reported ($2.53) EPS for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.13). BioNTech had a negative return on equity of 6.86% and a negative net margin of 63.54%.The firm had revenue of $122.31 million for the quarter, compared to analysts’ expectations of $180.18 million. During the same period last year, the firm earned ($1.60) earnings per share. BioNTech’s revenue for the quarter was down 59.5% on a year-over-year basis. On average, sell-side analysts predict that BioNTech SE Sponsored ADR will post -6.37 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

BNTX has been the subject of several analyst reports. Sanford C. Bernstein reiterated a “market perform” rating on shares of BioNTech in a research report on Friday, June 5th. BMO Capital Markets lowered BioNTech from an “outperform” rating to a “market perform” rating and decreased their price target for the company from $128.00 to $105.00 in a research note on Tuesday, September 8th. Morgan Stanley lowered their price target on BioNTech from $126.00 to $119.00 and set an “overweight” rating for the company in a report on Wednesday, July 8th. Citigroup cut their price objective on BioNTech from $130.00 to $125.00 and set a “buy” rating for the company in a research report on Wednesday, August 5th. Finally, Berenberg Bank set a $140.00 price objective on shares of BioNTech in a report on Wednesday, September 16th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, BioNTech has an average rating of “Moderate Buy” and a consensus target price of $126.00.

Institutional Trading of BioNTech

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Monaco Asset Management SAM acquired a new stake in shares of BioNTech in the fourth quarter valued at $1,594,000. Hsbc Holdings PLC acquired a new position in BioNTech during the 4th quarter worth about $4,969,000. Bank of America Corp DE lifted its stake in BioNTech by 22.6% during the 1st quarter. Bank of America Corp DE now owns 903,029 shares of the company’s stock worth $80,261,000 after acquiring an additional 166,432 shares in the last quarter. BNP Paribas Financial Markets boosted its holdings in BioNTech by 43.0% during the 4th quarter. BNP Paribas Financial Markets now owns 1,578,094 shares of the company’s stock valued at $150,235,000 after acquiring an additional 474,796 shares during the period. Finally, Amundi boosted its holdings in BioNTech by 24.5% during the 1st quarter. Amundi now owns 129,513 shares of the company’s stock valued at $11,511,000 after acquiring an additional 25,506 shares during the period. Hedge funds and other institutional investors own 15.52% of the company’s stock.

About BioNTech

BioNTech SE is a biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. Its research platforms include messenger RNA, cell therapies, protein-based therapeutics, antibody therapies and small-molecule immunomodulators.

The company is best known for Comirnaty, its COVID-19 vaccine developed and commercialized globally in collaboration with Pfizer. BioNTech is also advancing a broad oncology pipeline that includes individualized and off-the-shelf cancer vaccines, antibody-based treatments, cell therapies and combination approaches designed to stimulate or direct the immune system against tumors.

BioNTech was founded in 2008 and is headquartered in Mainz, Germany.